Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

Area of Science:

• Oncology
• Radiation Oncology
• Urology

Background:

• Androgen deprivation therapy (ADT) has been the standard for metastatic prostate cancer (mPC).
• Recent findings indicate ADT alone is suboptimal.
• Emerging treatments include taxanes, novel antiandrogens, and primary tumor radiotherapy.

Purpose of the Study:

• To review evidence for primary tumor radiotherapy in newly diagnosed mPC.
• To assess metastasis-directed therapy (MDT) in oligometastatic prostate cancer.
• To explore future directions in mPC treatment.

Main Methods:

• Literature review of clinical evidence.
• Analysis of studies on primary tumor radiotherapy.
• Evaluation of MDT in oligometastatic settings.

Main Results:

• Radiotherapy to the primary tumor shows promise in mPC.
• MDT is under investigation for oligometastatic hormone-sensitive prostate cancer with positive early results.
• Combined approaches are emerging as superior to ADT alone.

Conclusions:

• ADT alone is insufficient for newly diagnosed mPC.
• Radiotherapy and MDT represent evolving treatment strategies.
• Further research is needed to optimize these approaches for better patient outcomes.